Terminal Ileum Resection and Colorectal Cancer Risk in Crohn’s Disease: What 19 Years of Real-World Data Show

Key Takeaways

• In a large study of 27,234 CD patients, terminal ileum resection was associated with a 2.58-fold increase in colorectal cancer risk, a finding that held regardless of whether patients had colonic disease involvement. 
• Biologic therapy showed no protective effect against colorectal cancer risk in the resection group, a finding with direct implications for how post-surgical surveillance frameworks are designed and what intervention targets may need to be explored. 
• For HEOR teams, this evidence reshapes the long-term burden calculus for CD: surgery is not a clinical endpoint, and the downstream cancer risk it introduces has meaningful consequences for resource planning, value dossiers, and surveillance strategy. 

For most clinical frameworks, surgery in Crohn’s disease (CD) is understood as an intervention endpoint; the point at which medical management has been exhausted and a more definitive step is taken. What the evidence increasingly suggests is that surgery is better understood as a transition point, one that introduces a new and lasting set of clinical risks that current post-surgical surveillance standards may not adequately address. 

This independently conducted Brief Report by Mikhail et al. (Inflamm Bowel Dis. 2025 Sep 1;31(9):2593-2596) conducted utilizing the TriNetX LIVE™ platform makes that case in terms that Health Economics and Outcomes Research (HEOR) teams need to confront directly with additional research and contextualization. 

The Surveillance Gap Is Larger Than It Appears

Terminal ileum resection is a common surgical intervention in CD when medical therapy fails to control disease. What has been less well-characterized is what it means for long-term cancer risk. Specifically, whether the procedure itself elevates colorectal cancer risk independent of the disease activity that prompted it. 

This is not a trivial question for HEOR teams. If post-surgical cancer risk is driven primarily by ongoing inflammation or colonic disease burden, existing surveillance frameworks built around those factors may be adequate. If it is driven by the resection itself, through a mechanism independent of disease extent or biologic treatment status, the surveillance calculus changes significantly. Clearly more nuanced research is needed to put the findings in more context.  

The study provides important information with potential clinical implications. 

What the Study Found

Researchers used the TriNetX LIVE™ platform, drawing on real-world data (RWD) from U.S. healthcare organizations spanning 2005 to 2024. After propensity score matching on demographics, comorbidities including primary sclerosing cholangitis, surgical history, and medication use, the analysis included 13,617 patients in each cohort: those who underwent terminal ileum resection and those who did not. 

The primary finding is direct: patients who underwent terminal ileum resection had a 2.58-fold higher risk of developing colorectal cancer compared with unresected CD patients. 

Two additional findings sharpen the implications considerably. 

• The risk was independent of colonic disease involvement. Among patients with colonic disease, the adjusted hazard ratio was 2.57. Among patients without colonic involvement, it was 3.04. The elevated risk was not a function of where the disease was located. It was associated with the resection itself. 
• Biologic therapy did not modify the risk. Patients who received biologic treatments after resection showed no reduction in colorectal cancer risk. For HEOR teams, this is not just a clinical finding. It points toward a question worth examining: whether post-surgical surveillance frameworks are adequately calibrated for this population. 

The resection group also had a higher risk of benign colonic polyps, a known colorectal cancer precursor, adding a mechanistic step to the cancer risk pathway that warrants attention in surveillance protocol design. 

On mortality, all-cause mortality did not differ significantly between patients who developed colorectal cancer with prior resection and those with colorectal cancer alone. 

Why the Biology Matters for Outcomes Modeling

The study’s authors point to bile acid metabolism as the most plausible mechanism. The terminal ileum is the primary site of bile acid reabsorption. When it is resected, bile acids that would normally be reabsorbed pass into the colon in higher concentrations, where they can contribute to epithelial injury, chronic inflammation, oxidative stress, microbiome disruption, and, over time, tumorigenesis. 

This mechanism matters for HEOR frameworks for a specific reason: it is largely independent of inflammatory bowel disease (IBD) activity. A patient in clinical remission following resection, maintained on biologic therapy, may still be accumulating colorectal cancer risk through a pathway that standard IBD management does not address. The risk is long-horizon and persistent, which is exactly the kind of burden that longitudinal outcomes modeling needs to capture but often does not. 

For teams building budget impact models or long-term cost-effectiveness analyses around CD surgical interventions, the bile acid hypothesis also opens a question worth investigating: bile acid sequestrants and related interventions represent a potential future target for post-surgical risk reduction. If that line of research matures, it will require the kind of real-world population data to evaluate it that a network like TriNetX is positioned to provide. 

Implications for Surveillance Strategy and Resource Planning

Most colorectal cancer surveillance protocols in IBD are calibrated around disease duration, extent, and activity. This study suggests that resection history, specifically terminal ileum resection, may warrant its own weight in surveillance stratification, independent of those factors. For teams developing HEOR frameworks or supporting health technology assessment submissions, this is a meaningful input: the post-surgical patient population carries a distinct long-term risk profile that should be modeled separately, not folded into general IBD surveillance assumptions. 

For medical affairs teams, the finding also opens a straightforward but important case for enhanced colonoscopic monitoring in post-resection CD patients, a recommendation the study’s clinical implications support directly. 

Surgery does not end the clinical risk calculus for CD patients. For organizations building evidence-based frameworks around what CD management really costs over time, understanding what happens after resection is as important as what happens before. 

About Jeffrey Brown, PhD

With more than 25 years of experience in research and consulting, Jeff is an internationally recognized expert in the use of RWD to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of RWD resources.